As more insurers and employers use a new tool called copay accumulators to fend off copay assistance from drug makers, the pharmaceutical industry is fighting back with an analysis that suggests employers should think twice because they may be at risk for doing so.

Copay accumulators have been embraced over the past year by a growing number of insurers and employers in hopes of limiting prescription drug spending. The reason is that accumulators do not count the value of any copay assistance cards or coupons — which drug makers often readily provide — toward out-of-pocket medicine costs that are applied toward deductibles.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy